Life Sciences Portfolio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Life sciences portfolio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Life Sciences Portfolio Today - Breaking & Trending Today

Acacia Research Reports First Quarter 2024 Financial Results

Acacia Research Reports First Quarter 2024 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , D Mcnulty Jr , Arix Bioscience Plc , Acacia Research Corporation , Board Of Directors The Company , Acacia Research Corporation Nasdaq , Life Sciences Portfolio , Acacia Research Reports First Quarter , Novabiotics Ltd , Company Annual Report On Form , Viamet Pharmaceuticals Inc , Pharma Ltd , Research Reports First Quarter , Research Corporation , Chief Executive Officer , Benchmark Energy , Western Anadarko Basin , Texas Panhandle , Arix Bioscience , Intellectual Property , Profits Interests Plan , Viamet Pharmaceuticals , Private Securities Litigation Reform Act , Starboard Value , Annual Report ,

Acacia Research Reports Third Quarter 2023 Financial Results

Acacia Research Reports Third Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Rob Fink , Martind Mcnulty Jr , Arix Bioscience , Company Board Of Directors , Acacia Research Corporation , Company Annual Report On Form , Biotech Opportunities Ltd , Acacia Research Corporation Nasdaq , Life Sciences Portfolio , Company Series , Viamet Pharmaceuticals Inc , United Kingdom Financial Conduct Authority , Research Corporation , Financial Conduct , Benchmark Energy , Interim Chief Executive Officer , Intellectual Property , Viamet Pharmaceuticals , Rights Offering , Private Rights Offering , Senior Secured Notes , Seriesb Warrants , Redeemable Convertible Preferred Stock , Private Securities Litigation Reform Act ,

Acacia Research Reports Second Quarter 2023 Financial Results

Acacia Research Corporation today reported financial results for the three and six months ended June 30, 2023.

Key Business Highlights

On July 13, 2023, completed its recapitalization. ....

Martind Mcnulty Jr , Arix Bioscience , Viamet Pharmaceuticals Inc , Acacia Research Corporation Nasdaq , Company Series , Company Seriesb Warrants The Series , Acacia Research Corporation , Company Annual Report On Form , Life Sciences Portfolio , Starboard Value , Convertible Preferred Stock , Common Stock , Seriesb Warrants , Recapitalization Transactions , Months Ended June , Interim Chief Executive Officer , Intellectual Property , Viamet Pharmaceuticals , Rights Offering , Private Rights , Senior Secured Notes , Adjusted Book Value , Private Securities Litigation Reform Act , Annual Report , Preferred Conversion ,

Acacia Research Reports First Quarter 2023 Financial Results

Acacia Research Corporation today reported financial results for the three months ended March 31, 2023.

Key Business Highlights

Executed a Rights Offering , raising $79.1 million in net. | May 11, 2023 ....

Martind Mcnulty Jr , Arix Bioscience , Company Series , Acacia Research Corporation , Viamet Pharmaceuticals Inc , Exchange Commission , Acacia Research Corporation Nasdaq , Company Annual Report On Form , Life Sciences Portfolio , Rights Offering , Months Ended March , Interim Chief Executive Officer , Intellectual Property , Viamet Pharmaceuticals , Senior Secured Notes , Adjusted Book Value , Annual Meeting , Securities Act , Annual Report , Private Securities Litigation Reform Act , Starboard Value , Preferred Conversion , Acacia Research Corporation Stock Exchange , Press Release , N Actg Us0038813079 ,

Norton Rose Fulbright advises on ADQ's acquisition of Birgi Mefar Group

Global law firm Norton Rose Fulbright advised the shareholders of Turkish pharmaceuticals company Birgi Mefar Group (BMG) on the sale of 100% of its shares to Abu Dhabi investment and holding company ADQ. BMG is one of Turkey’s leading producers of sterile injectable products, such as vials and pre-filled syringes . ....

Abu Dhabi , Claire Odonnell , Matt Foster , Bayar Mizrahi , Norton Rose Fulbright , Birgi Mefar Group , Life Sciences Portfolio , Abu Dhabi Based , Rose Fulbright , Claireo Donnell , Pekin Bayar Mizrahi , Life Sciences ,